PRQR — ProQR Therapeutics NV Balance Sheet
0.000.00%
- $150.38m
- $59.57m
- €9.53m
Annual balance sheet for ProQR Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 112 | 75.8 | 188 | 94.8 | 119 |
Net Total Receivables | 0.34 | 0.379 | 0.268 | 56.6 | 0.745 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 115 | 80 | 191 | 154 | 121 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.44 | 18.6 | 17.5 | 16.2 | 16.9 |
Long Term Investments | |||||
Total Assets | 118 | 98.7 | 210 | 171 | 138 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 11 | 10.3 | 27.6 | 21.1 | 34.2 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 23.2 | 41.6 | 95.7 | 106 | 96.5 |
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Total Equity | 94.3 | 57.1 | 114 | 65.5 | 41.4 |
Total Liabilities & Shareholders' Equity | 118 | 98.7 | 210 | 171 | 138 |
Total Common Shares Outstanding |